Paxil CR Labeling Adds Birth Defects Warning Based On U.S., Swedish Data
Executive Summary
FDA deemed a birth defects warning for GlaxoSmithKline's Paxil CR to be warranted after data from a Swedish birth registry supported an analysis of a U.S. managed care claims database, the agency said
You may also be interested in...
Paxil CR Labeling Adds New Data On Birth Defects; GSK Plans Further Studies
GlaxoSmithKline is conducting additional epidemiologic studies to better understand preliminary data suggesting a potential link between paroxetine use and birth defects, the company said in a "Dear Doctor" letter on revised labeling for Paxil CR and Paxil
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials